WO2012092486A3 - Formulations de benzimidazole à libération modifiée - Google Patents

Formulations de benzimidazole à libération modifiée Download PDF

Info

Publication number
WO2012092486A3
WO2012092486A3 PCT/US2011/067868 US2011067868W WO2012092486A3 WO 2012092486 A3 WO2012092486 A3 WO 2012092486A3 US 2011067868 W US2011067868 W US 2011067868W WO 2012092486 A3 WO2012092486 A3 WO 2012092486A3
Authority
WO
WIPO (PCT)
Prior art keywords
modified release
benzimidazole
formulations
drug
benzimidazole formulations
Prior art date
Application number
PCT/US2011/067868
Other languages
English (en)
Other versions
WO2012092486A2 (fr
Inventor
Lingam MEKA
Srinivasa Almareddy REDDY
Vagisha SINHA
Hitesh JOGIA
Srinivas Arutla
Raviraj PILLAI
Rahul Sudhakar Gawande
Prasad Vure
Venkateswarlu Vobalaboina
Original Assignee
Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Laboratories Ltd., Dr. Reddy's Laboratories, Inc. filed Critical Dr. Reddy's Laboratories Ltd.
Priority to UAA201309355A priority Critical patent/UA112855C2/uk
Priority to CN201180068674XA priority patent/CN103402501A/zh
Priority to EA201390979A priority patent/EA201390979A1/ru
Priority to EP11853533.5A priority patent/EP2661260A4/fr
Priority to NZ613090A priority patent/NZ613090A/en
Priority to AU2011352037A priority patent/AU2011352037A1/en
Publication of WO2012092486A2 publication Critical patent/WO2012092486A2/fr
Publication of WO2012092486A3 publication Critical patent/WO2012092486A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne une formulation pharmaceutique permettant plus d'une libération de médicament benzimidazole. Dans des modes de réalisation, des particules contenant le médicament sont enrobées avec au moins un polymère ayant une solubilité à des valeurs de pH d'environ 5 à environ 7,5 et d'autres particules contenant le médicament sont enrobées avec au moins un polymère ayant une solubilité à des valeurs de pH d'environ 5 à environ 6.
PCT/US2011/067868 2010-12-29 2011-12-29 Formulations de benzimidazole à libération modifiée WO2012092486A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
UAA201309355A UA112855C2 (uk) 2010-12-29 2011-12-29 Композиції бензімідазолів з модифікованим вивільненням
CN201180068674XA CN103402501A (zh) 2010-12-29 2011-12-29 调节释放的苯并咪唑制剂
EA201390979A EA201390979A1 (ru) 2010-12-29 2011-12-29 Композиции бензимидазолов с модифицированным высвобождением
EP11853533.5A EP2661260A4 (fr) 2010-12-29 2011-12-29 Formulations de benzimidazole à libération modifiée
NZ613090A NZ613090A (en) 2010-12-29 2011-12-29 Modified release benzimidazole formulations
AU2011352037A AU2011352037A1 (en) 2010-12-29 2011-12-29 Modified release benzimidazole formulations

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN4013CH2010 2010-12-29
IN4013/CHE/2010 2010-12-29
US201161447759P 2011-03-01 2011-03-01
US61/447,759 2011-03-01

Publications (2)

Publication Number Publication Date
WO2012092486A2 WO2012092486A2 (fr) 2012-07-05
WO2012092486A3 true WO2012092486A3 (fr) 2012-11-01

Family

ID=46383862

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/067868 WO2012092486A2 (fr) 2010-12-29 2011-12-29 Formulations de benzimidazole à libération modifiée

Country Status (7)

Country Link
EP (1) EP2661260A4 (fr)
CN (1) CN103402501A (fr)
AU (1) AU2011352037A1 (fr)
EA (1) EA201390979A1 (fr)
NZ (1) NZ613090A (fr)
UA (1) UA112855C2 (fr)
WO (1) WO2012092486A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2667402T3 (es) * 2011-11-02 2018-05-10 Laboratorios Del Dr. Esteve, S.A. Composición farmacéutica de omeprazol
AU2014215478B2 (en) * 2013-02-05 2018-09-13 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
WO2014142938A1 (fr) * 2013-03-15 2014-09-18 Aihol Corporation Formulation pharmaceutique contenant un glycosaminoglycane
WO2016174664A1 (fr) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Compositions à désintégration par voie orale
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN112336696B (zh) * 2020-12-01 2022-08-05 苏州中化药品工业有限公司 一种长效脉冲制剂及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US20060013868A1 (en) * 2002-10-16 2006-01-19 Yohko Akiyama Controlled release preparation
US20080095853A1 (en) * 2004-11-04 2008-04-24 Niclas Clemmensen Modified Release For Proton Pump Inhibitors
US20090028941A1 (en) * 2007-07-27 2009-01-29 Depomed, Inc. Pulsatile gastric retentive dosage forms
US20090214599A1 (en) * 2008-02-21 2009-08-27 Agi Therapeutics Plc Proton pump inhibitor formulations, and methods of preparing and using such formulations
US20090220611A1 (en) * 2005-09-30 2009-09-03 Frederic Dargelas Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4541807B2 (ja) * 2004-09-03 2010-09-08 Ｏｋｉセミコンダクタ株式会社 半導体素子保持装置および半導体素子の搬送方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US20060013868A1 (en) * 2002-10-16 2006-01-19 Yohko Akiyama Controlled release preparation
US20080095853A1 (en) * 2004-11-04 2008-04-24 Niclas Clemmensen Modified Release For Proton Pump Inhibitors
US20090220611A1 (en) * 2005-09-30 2009-09-03 Frederic Dargelas Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same
US20090028941A1 (en) * 2007-07-27 2009-01-29 Depomed, Inc. Pulsatile gastric retentive dosage forms
US20090214599A1 (en) * 2008-02-21 2009-08-27 Agi Therapeutics Plc Proton pump inhibitor formulations, and methods of preparing and using such formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2661260A4 *

Also Published As

Publication number Publication date
UA112855C2 (uk) 2016-11-10
AU2011352037A1 (en) 2013-08-01
EA201390979A1 (ru) 2013-12-30
EP2661260A2 (fr) 2013-11-13
EP2661260A4 (fr) 2014-05-14
WO2012092486A2 (fr) 2012-07-05
CN103402501A (zh) 2013-11-20
NZ613090A (en) 2015-11-27

Similar Documents

Publication Publication Date Title
WO2012092486A3 (fr) Formulations de benzimidazole à libération modifiée
WO2011116963A3 (fr) Capsules de nanoparticules de lipide
MX348491B (es) Tableta a prueba de manipulacion que proporciona liberacion inmediata de fármaco.
WO2012035429A3 (fr) Systèmes d'administration de médicament télécommandés
WO2012034079A3 (fr) Formes pharmaceutiques de type macrolides
WO2011084620A3 (fr) Particules pour administration de plusieurs agents
WO2008132229A3 (fr) Solutions et compositions hautement concentrées en insuline
EA033370B1 (ru) Составы рифаксимина и их применение
MX2015000114A (es) Composiciones farmaceuticas disuasivas de abuso de liberacion prolongada.
MX2013001985A (es) Formulaciones a base de nalbufina y sus usos
WO2010021607A3 (fr) Préparation pharmaceutique
WO2010005732A3 (fr) Composition et procédé de préparation de systèmes de libération pour la libération constante (d’ordre zéro) d’agents actifs
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
WO2011067667A3 (fr) Microcapsules de fexofénadine et compositions les contenant
UA103025C2 (ru) Твердая композиция лекарственного средства замедленного высвобождения
PH12014502191A1 (en) Capsule disintegrable in large-intestine-specific manner
WO2012001705A3 (fr) Compositions pharmaceutiques de (r)-lansoprazole
WO2011037976A3 (fr) Formulations pharmaceutiques de pramipexole
WO2012085284A3 (fr) Formulations pharmaceutiques à charge médicamenteuse élevée comprenant de la dronédarone et des sels pharmaceutiquement acceptables de celles-ci
WO2012172433A3 (fr) Composition à libération prolongée contenant des peptides en tant que principes actifs
WO2012085249A3 (fr) Formes pharmaceutiques orales homogènes comprenant de la lercanidipine et de l'énalapril ou leurs sels pharmaceutiquement acceptables
WO2012074830A3 (fr) Formulation d'acide tranexamique à libération modifiée
WO2012023024A3 (fr) Formulations de dronédarone à libération contrôlée
MX346316B (es) Formulacion farmaceutica o nutraceutica.
DK2391352T3 (da) Farmaceutiske former til frigivelse af aktive forbindelser

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11853533

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2011853533

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011853533

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: A201309355

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 201390979

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2011352037

Country of ref document: AU

Date of ref document: 20111229

Kind code of ref document: A